A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

T elemedicine company GoodRx ( GDRX) has been helping Americans find the cheapest way to buy drugs for years. Thanks to a new ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Can Novo Nordisk and Eli Lilly regain their former stock market glory? A lot is riding on next year's pills ...

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk A/S said it has implemented a global hiring freeze as the Danish maker of weight-loss drugs seeks to cut costs ...